PO.ET04.01 · 实验与分子治疗

Bioluminescent tools for quantification of in vivo CAR‑T delivery systems

海报缩略图:Bioluminescent tools for quantification of in vivo CAR‑T delivery systems
编号 275 展板 18 时间 4/19 02:00–05:00 区域 Section 12 主讲 Steven Edenson, BS;MBA
分会场 Gene and Vector-Based Therapy
查看完整资料 下载 PDF 登录后可访问当前开放资料 AACR 官方页面 ↗

作者与单位

Julia K. Gilden1, Pete Stecha2, Rich Moravec2, Jun Wang3, Rod Flemming1, Jim Harnett1, Steven Edenson1, Kristin Riching1, Jamison Grailer1, Mei Cong2

1Promega, Madison, WI,2R&D, Promega, Madison, WI,3Promega, Fitchburg, WI

摘要 Abstract

In vivo CAR‑T engineering using mRNA-LNP, lentiviral (LV), or AAV vectors requires analytical methods that are rapid, scalable, and mechanistically informative across CMC and bioassay workflows. We assembled an integrated luminescent toolkit to quantify vector input, functional potency, and innate‑immune risk. For mRNA-LNP, a Lumit® dsRNA detection assay uses a split luciferase system to quantify double‑stranded RNA impurities that can trigger innate sensing and diminish transfection. For broader assessment of immunogenicity, cell‑based TLR reporter assays profile vector‑ or formulation‑induced pathway activation. For quantification of LV vectors, the homogeneous, no‑wash Lumit® p24 Immunoassay measures the LV p24 capsid protein as a surrogate for viral particle count with a wide linear range in ~60 minutes. Functional potency can be measured using a cell-based reporter bioassay in which Jurkat T cells stably expressing an NFAT-Luc2 reporter are transduced with CAR LV and co‑cultured with antigen‑positive targets to generate an antigen‑dependent luminescent signal that reflects LV identity and potency. Together, these assays streamline development, release, and comparability for in vivo CAR‑T delivery systems.
利益披露 Disclosure
J. K. Gilden, None.. P. Stecha, None.. R. Moravec, None.. J. Wang, None.. R. Flemming, None.. J. Harnett, None.. S. Edenson, None.. K. Riching, None.. J. Grailer, None.. M. Cong, None.

在会议检索中打开